Bristol-Myers Squibb
ORG
Bristol-Myers Squibb Bristol-Myers
Sanofi-Aventis and its partner Bristol-Myers Squibb said late yesterday that they had tentatively settled a patent dispute involving Plavix, the anticlotting agent that is the world's second-best-selling drug. The settlement, which needs approval by the Federal Trade Commission, was considered a positive development for both Sanofi-Aventis, a French company, and Bristol-Myers Squibb, which is based in New York. In after-hours trading, shares of Bristol-Myers climbed $1.92, to $24.75.